Program
ganfeborole
In GlaxoSmithKline's pipeline, Leucyl t-RNA synthetase inhibitor
. Its studies are mostly in Tuberculosis, Pulmonary · Tuberculosis, led by GlaxoSmithKline.
Furthest: phase 2, since Jun 4, 20184 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 40 open or running | phase 2since Jun 4, 2018 | Mar 6, 2017 | none ahead |
- Named in GlaxoSmithKline’s own pipeline as
ganfeborole GSK3036656
, phase 2, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 6, 2017First study: phase 1 study in TuberculosisFirst studyNCT03075410 · 30 enrolled · United Kingdom
- Jun 4, 2018Phase 2 study in TuberculosisNCT03557281 · 76 enrolled · South Africa
- May 16, 2022Phase 2 study in TuberculosisNCT05382312 · 127 enrolled · South Africa
- Apr 3, 2024Phase 1 study in TuberculosisNCT06354257 · 20 enrolled · Spain
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Leucyl t-RNA synthetase inhibitor”the company's pipeline, read by Claude · source
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06354257Tuberculosis · Spain | 1 | Completed | Jul 1, 2024 | 20 |
| NCT05382312Tuberculosis · South Africa | 2 | Completed | May 27, 2025 | 127 |
| NCT03557281Tuberculosis · South Africa | 2 | Completed | Dec 3, 2021 | 76 |
| NCT03075410Tuberculosis · United Kingdom | 1 | Completed | Aug 4, 2017 | 30 |
How it is read
Names in the registry
- “GSK3036656”, 4 entries
Conditions, from the studies’ own filings
- Tuberculosis, Pulmonary, 2 studies
- Tuberculosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.